Baseline Genotypic and Phenotypic Susceptibilities of HIV-1 Group O to Enfuvirtide-Reference-Cited by-同舟云学术

Baseline Genotypic and Phenotypic Susceptibilities of HIV-1 Group O to Enfuvirtide

Published:2010-09 Issue:9 Volume:54 Page:4016-4019
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Depatureaux Agnès¹,Charpentier Charlotte¹,Collin Gilles²,Leoz Marie¹,Descamps Diane²,Vessière Aurélia³,Damond Florence²,Rousset Dominique³,Brun-Vézinet Françoise²,Plantier Jean-Christophe¹

Affiliation:

1. Laboratoire associé au Centre National de Référence du VIH, EA2656, CHU Charles Nicolle, Rouen

2. Assistance Publique—Hôpitaux de Paris (AP-HP), Hôpital Bichat-Claude Bernard, Laboratoire de Virologie, Paris, France

3. Centre Pasteur du Cameroun, Yaoundé, Cameroon

Abstract

ABSTRACT We assessed the natural genotypic and phenotypic susceptibilities to enfuvirtide of 171 HIV group O (HIV-O) samples and 29 strains, respectively. The N42D resistance-associated mutation in the gp41 region was detected in 98% of cases. The phenotypic assay showed a wide range of baseline susceptibilities, with 50% inhibitory concentrations (IC 50 s) from 4 to 5,000 nM, a range similar to that reported for HIV-1 group M. Thus, despite the natural genotypic resistance conferred by the N42D signature mutation, HIV-O variants appear to be phenotypically susceptible. Enfuvirtide could therefore potentially be used in antiretroviral treatments for HIV-O-infected patients.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00100-10

Reference28 articles.

1. Agut, H., D. Candotti, B. Rabanel, J. M. Huraux, G. Remy, D. Ingrand, T. Tabary, C. Chippaux, S. Chamaret, D. Guetard, and L. Montagnier. 1992. Isolation of atypical HIV-1-related retrovirus from an AIDS patient. Lancet340:681-682.

2. Ayouba, A., P. Mauclère, P. M. Martin, P. Cunin, J. Mfoupouendoun, B. Njinku, S. Souquières, and F. Simon. 2001. HIV-1 group O infection in Cameroon, 1986 to 1998. Emerg. Infect. Dis.7:466-467.

3. Charneau, P., A. M. Borman, C. Quillent, D. Guétard, S. Chamaret, J. Cohen, G. Rémy, L. Montagnier, and F. Clavel. 1994. Isolation and envelope sequence of a highly divergent HIV-1 isolate: definition of a new HIV-1 group. Virology205:247-253.

4. Chinnadurai, R., J. Münch, M. T. Dittmar, and F. Kirchhoff. 2005. Inhibition of HIV-1 group M and O isolates by fusion inhibitors. AIDS19:1919-1922.

5. de Baar, M. P., W. Janssens, A. de Ronde, K. Fransen, R. Colebunders, L. Kestens, G. van der Groen, and J. Goudsmit. 2000. Natural residues versus antiretroviral drug-selected mutations in HIV type 1 group O reverse transcriptase and protease related to virological drug failure in vivo. AIDS Res. Hum. Retroviruses16:1385-1394.

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In vitrophenotypic susceptibility of HIV-1 non-group M to CCR5 inhibitor (Maraviroc): TROPI-CO study;2023-10-22

2. HIV-1 Non-Group M Strains and ART;Viruses;2023-03-17

3. HIVfird: A Tool for Detection of Resistance to Fusion Inhibitor Drugs in HIV-1 Sequences;AIDS Research and Human Retroviruses;2019-10-01

4. HIV-1 non-group M phenotypic susceptibility to integrase strand transfer inhibitors;Journal of Antimicrobial Chemotherapy;2017-07-06

5. HIV-1 Group O Genotypes and Phenotypes: Relationship to Fitness and Susceptibility to Antiretroviral Drugs;AIDS Research and Human Retroviruses;2016-07